黛力新治疗冠心病心肌梗死后合并焦虑症状患者的临床疗效观察

目的分析冠状动脉粥样硬化性心脏病(冠心病)心肌梗死后合并焦虑症状患者采用氟哌噻吨美利曲辛片(商品名:黛力新)治疗的临床效果。方法80例冠心病心肌梗死后合并焦虑症状患者,采用随机数字表法分为对照组与干预组,每组40例。对照组开展规范化常规治疗,干预组在对照组基础上给予黛力新治疗。比较治疗前后两组患者的心率与血压水平、焦虑自评量表(SAS)评分,并进行临床疗效评价。结果治疗4周后,干预组的心率、收缩压、舒张压分别为(88.5±7.2)次/min、(133.5±6.2)mm Hg(1 mm Hg=0.133 kPa)、(90.1±5.9)mm Hg,对照组分别为(92.5±7.8)次/min、(142.0±6.4)mm Hg、(95.8±6.6)mm Hg;治疗12周后,干预组的心率、收缩压、舒张压分别为(84.2±6.7)次/min、(128.2±7.3)mm Hg、(82.4±6.3)mm Hg,对照组分别为(88.0±7.5)次/min、(138.0±8.9)mm Hg、(90.5±7.0)mm Hg,治疗4周后和治疗12周后,两组的心率、收缩压、舒张压均较治疗前降低,且干预组降低幅度大于对照组,差异有统计学意义(P<0.05)。治疗4周后,干预组的SAS评分为(51.27±5.52)分,对照组为(55.32±6.37)分,治疗12周后,干预组的SAS评分为(39.56±5.96)分,对照组为(50.31±8.79)分。治疗4周后和治疗12周后,两组的SAS评分均较治疗前降低,且干预组降低幅度大于对照组,差异有统计学意义(P<0.05)。干预组的治疗总有效率90.00%高于对照组的67.50%,差异有统计学意义(P<0.05)。结论基于规范化常规治疗,对冠心病心肌梗死后合并焦虑症状患者进行黛力新治疗,有助于焦虑症状明显改善,有利于稳定血压和心率,促进病情恢复。

Observation on the clinical efficacy of Deanxit in treating patients with anxiety symptoms after myocardial infarction of coronary heart disease

Objective To analyze the clinical effect of flupentixol and melitracen tablets(trade name:Deanxit)in treating patients with anxiety symptoms after myocardial infarction of coronary heart disease.Methods A total of 80 patients with anxiety symptoms after myocardial infarction of coronary heart disease were divided into control group and intervention group by random number table method,with 40 cases in each group.The control group received standardized routine therapy,and the intervention group received Deanxit for treatment on the basis of the control group.The heart rate and blood pressure level and self-rating scale(SAS)score before and after treatment and clinical efficacy were compared between the two groups.Results After 4 weeks of treatment,the heart rate,systolic blood pressure and diastolic blood pressure were(88.5±7.2)times/min,(133.5±6.2)mm Hg(1 mm Hg=0.133 kPa)and(82.4±6.3)mm Hg respectively in the research group,which were(92.5±7.8)times/min,(142.0±6.4)mm Hg and(95.8±6.6)mm Hg respectively in the control group.After 12 weeks of treatment,the heart rate,systolic blood pressure and diastolic blood pressure were(84.2±6.7)times/min,(128.2±7.3)mm Hg and(90.1±5.9)mm Hg respectively in the research group,which were(88.0±7.5)times/min,(138.0±8.9)mm Hg and(90.5±7.0)mm Hg respectively in the control group.After 4 and 12 weeks of treatment,the heart rate,systolic blood pressure and diastolic blood pressure in the two groups was lower than those before treatment,and the decline in the intervention group was greater than that of the control group.Their difference was statistically significant(P<0.05).After 4 weeks of treatment,the SAS score was(51.27±5.52)points,which was(55.32±6.37)points in the control group.After 12 weeks of treatment,the SAS score was(39.56±5.96)points,which was(50.31±8.79)points in the control group.After 4 and 12 weeks of treatment,the SAS score in the two groups was lower than those before treatment,and the decline in the intervention group was greater than that of the control group.Their difference was statistically significant(P<0.05).The total effective rate of treatment 90.00%in the intervention group was higher than 67.50%in the control group,and the difference was statistically significant(P<0.05).Conclusion Based on the standardized routine treatment,Deanxit is helpful to improve the anxiety symptoms,stabilize blood pressure and heart rate of patients with anxiety symptoms after myocardial infarction of coronary heart disease,and promote their recovery.